<DOC>
	<DOCNO>NCT02916446</DOCNO>
	<brief_summary>This study evaluate safety Viaskin Peanut 250 mcg treatment peanut allergy child 4 11 year age . Subjects receive either Viaskin Peanut 250 mcg placebo period 6 month , subject receive active treatment period 3 year active treatment .</brief_summary>
	<brief_title>Safety Study Viaskin Peanut Treat Peanut Allergy</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Physiciandiagnosed peanut allergy ; A peanut Skin Prick Test ( SPT ) wheal large diameter ≥8 mm ; A specificpeanut Immunoglobulin E ( IgE ) ≥14 kU/L ; Subjects follow strict peanutfree diet . Generalized dermatologic disease Spirometry force expiratory volume 1 second ( FEV1 ) &lt; 80 % predict value , peak expiratory flow ( PEF ) &lt; 80 % predict value ; Receiving βblocking agent , angiotensinconverting enzyme inhibitor , angiotensinreceptor blocker , calcium channel blocker tricyclic antidepressant therapy ; antitumor necrosis factor drug antiIgE drug ( omalizumab ) biologic immunomodulatory therapy ; Prior concomitant history immunotherapy food allergy ( example EPIT , OIT , SLIT , specific oral tolerance induction ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>